Home
Scan
Ask
Protocols
Profile
HomeIngredientsEchinacea
Reviewed by the Scan Dose Research Team and Clinical Advisory Board

Echinacea

MODERATE EVIDENCEBotanicalLast updated April 2026

SCAN DOSE SUMMARY

Echinacea is one of the most popular herbal supplements for immune support, but our research shows the evidence is frustratingly inconsistent. Some trials show modest cold duration reduction (12-24 hours shorter), others show nothing. Species matters (E. purpurea vs E. angustifolia), plant part matters (aerial parts vs root), and extract type matters. Overall verdict: possibly helpful if started at first symptoms, unlikely to prevent colds.

EVIDENCE GRADES

Common cold duration (treatment)Inconsistent — Cochrane review mixed (PMID: 24554461)
C+
Common cold preventionWeak — most prevention trials negative
C
Upper respiratory infection severitySome positive signals
C+
Immune cell activationIn vitro and ex vivo data strong
B-
Anxiety (E. angustifolia)Very preliminary
C

WHAT IT DOES

Echinacea contains alkamides, caffeic acid derivatives (cichoric acid, echinacoside), and polysaccharides. Alkamides modulate immune function via CB2 cannabinoid receptors and TNF-α. Different species and plant parts contain different active compound profiles:

  • E. purpurea aerial parts: Most studied for cold treatment. Rich in alkamides and cichoric acid.
  • E. purpurea root: Different compound profile; less commonly studied.
  • E. angustifolia root: Rich in echinacoside; studied for anxiety.
  • E. pallida root: Used in German phytomedicine.

OPTIMAL DOSAGE

  • Cold treatment (E. purpurea): 2,400mg/day extract or 4,000-6,000mg dried herb, started within 24 hours of symptoms, for 7-10 days
  • Prevention: 2,400mg/day for 4 months (evidence weak)
  • Echinaforce (branded): 4,000mg/day at onset (PMID: 25784510)
  • Duration: Do not take continuously for >8 weeks — efficacy may decrease
Scan a supplement containing Echinacea

DRUG INTERACTIONS

Immunosuppressants (cyclosporine, tacrolimus)Severe

Echinacea stimulates immune function — opposes immunosuppression

CYP3A4 substratesModerate

Echinacea may inhibit CYP3A4 short-term but induce it with chronic use — unpredictable

CYP1A2 substrates (caffeine, theophylline)Moderate

Moderate CYP1A2 inhibition documented

CorticosteroidsModerate

Opposes immunosuppressive effects

SAFETY PROFILE

Drug Interactions

Side Effects

  • GI effects (nausea) — uncommon
  • Allergic reactions (more common in atopic individuals and those with ragweed/daisy allergy — Asteraceae family cross-reactivity)
  • Rare anaphylaxis cases reported

Pregnancy & Lactation

  • Limited safety data. One prospective study found no increase in malformations, but data is insufficient for recommendation.

WADA Status

Not Prohibited

HOW SCAN DOSE SCORES THIS

Species + plant part identification critical — "Echinacea" alone is insufficient labeling
Autoimmune/immunosuppressant screen: automatic flag
Products for continuous prevention (>8 weeks): flag diminishing returns
Asteraceae allergy warning for atopic users
Branded extracts with clinical data (Echinaforce) score higher than generic

CLINICAL REFERENCES

1.

Karsch-Völk M et al. Echinacea for preventing and treating the common cold. *Cochrane Database Syst Rev.* 2014.

(2014). PMID: 24554461

2.

Jawad M et al. Safety and efficacy of Echinaforce® for preventing common cold episodes.

PMID: 25784510

3.

Barret B. Medicinal properties of Echinacea: a critical review.

PMID: 12807305

RELATED RESEARCH

Apigenin
ApigeninChamomile extract
Apocynum Venetum
ArjunaArjuna bark
Scan Your Echinacea SupplementBrowse all ingredients

Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated: April 2026

Not medical advice. Based on published clinical research and systematic reviews.

Discover More

Explore
Browse All 538 IngredientsBrowse All 20 Conditions